|
Treanda will generate robust revenue- I'm not sure whether it will become a $1B/yr drug.
However, the biologics recently acquired by CEPH will be blockbusters, and valuation of CEPH will reflect that as investors become aware of the prospects with this BT. Rating :
 (No ratings) |
51/Male |
|
Page
1
of about
1
First
| < Prev
| Next >
| Last
|
|
Page
1
of about
1
First
| < Prev
| Next >
| Last
|
0.53